LSA
ALNY icon

L & S Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

L & S Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-9,330
Closed -$1.36M – 235
2022
Q2 		$1.36M Buy
+9,330
New +$1.32M 0.23% 103
2020
Q3 		– Sell
-4,750
Closed -$704K – 298
2020
Q2 		$704K Buy
4,750
+2,409
+103% +$325K 0.11% 198
2020
Q1 		$255K Sell
2,341
-2,902
-55% -$335K 0.05% 215
2019
Q4 		$604K Buy
+5,243
New +$523K 0.08% 195

Other funds holding ALNY

Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

L & S Advisors's ALNY Position: Q3 2022 in Review

L & S Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2022, closing a stake of 9,330 shares — an estimated $1.36M sold.

L & S Advisors first reported a position in ALNY in Q4 2019 and held it in 4 quarters. The position peaked at $1.36M in Q2 2022. 497 funds tracked by Wall St. Rank hold ALNY as of Q3 2022.

  • L & S Advisors reported no remaining Alnylam Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • L & S Advisors sold 9,330 Alnylam Pharmaceuticals shares in Q3 2022, an estimated $1.36M.
  • L & S Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2019 and held it in 4 quarters.
  • L & S Advisors's Alnylam Pharmaceuticals position peaked at $1.36M in Q2 2022.
  • 497 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2022.

Based on L & S Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.